Epidemiology and Risk Factors for Infection in Multiple Myeloma Patients Treated With Bispecific Antibodies
Eduardo Aparicio-Minguijón, Nieves López-Muñoz, Guillermo Bartolomé Herguedas, Adolfo Jesús Sáez Marín, María Asunción Pérez-Jacoiste Asín, José María Sánchez-Pina, María Calbacho, Jorge Boán, Francisco López-Medrano, Rafael San Juan, José Tiago Silva, Joaquín Martínez-López, José María Aguado, Mari · 2026
Read Epidemiology and Risk Factors for Infection in Multiple Myeloma Patients Treated With Bispecific Antibodies by Eduardo Aparicio-Minguijón, Nieves López-Muñoz, Guillermo Bartolomé Herguedas, Adolfo Jesús Sáez Marín, María Asunción Pérez-Jacoiste Asín, José María Sánchez-Pina, María Calbacho, Jorge Boán, Francisco López-Medrano, Rafael San Juan, José Tiago Silva, Joaquín Martínez-López, José María Aguado, Mari (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13481984.txt.
Description
BackgroundBispecific antibodies (BsAbs) have revolutionized multiple myeloma (MM) treatment but are associated with infectious complications. This study aims to characterize the incidence, microbiological patterns, and risk factors for infection in this population.MethodsWe conducted an observational cohort study of adult MM patients treated with BsAbs at a single center between 2020 and 2025.
Catalog record
| CREATOR | Eduardo Aparicio-Minguijón, Nieves López-Muñoz, Guillermo Bartolomé Herguedas, Adolfo Jesús Sáez Marín, María Asunción Pérez-Jacoiste Asín, José María Sánchez-Pina, María Calbacho, Jorge Boán, Francisco López-Medrano, Rafael San Juan, José Tiago Silva, Joaquín Martínez-López, José María Aguado, Mari |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |